{"analyses":[{"ciLowerLimit":"4.23","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"17.73","groupDescription":"Cycle 2 Day 1: Physical Functioning","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Least-squares mean difference","paramValue":"11.0"},{"ciLowerLimit":"-20.18","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"-0.52","groupDescription":"Cycle 2 Day 1: Pain","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Least-squares mean difference","paramValue":"-10.4"},{"ciLowerLimit":"-6.65","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"13.91","groupDescription":"Cycle 2 Day 1: Appetite Loss","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Least-squares mean difference","paramValue":"3.6"},{"ciLowerLimit":"3.85","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"20.78","groupDescription":"Cycle 3 Day 1: Physical Functioning","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Least-squares mean difference","paramValue":"12.3"},{"ciLowerLimit":"-8.74","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"17.04","groupDescription":"Cycle 3 Day 1: Pain","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Least-squares mean difference","paramValue":"4.1"},{"ciLowerLimit":"-17.46","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"10.11","groupDescription":"Cycle 3 Day 1: Appetite Loss","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Least-squares mean difference","paramValue":"-3.7"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.75","value":"-2.4"},{"groupId":"OG001","spread":"2.95","value":"-13.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"title":"Cycle 2 Day 1: Physical Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.48","value":"2.2"},{"groupId":"OG001","spread":"4.35","value":"12.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"title":"Cycle 2 Day 1: Pain"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.60","value":"7.9"},{"groupId":"OG001","spread":"4.55","value":"4.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"title":"Cycle 2 Day 1: Appetite Loss"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.89","value":"-0.2"},{"groupId":"OG001","spread":"3.88","value":"-12.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Cycle 3 Day 1: Physical Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.73","value":"-1.2"},{"groupId":"OG001","spread":"5.96","value":"-5.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Cycle 3 Day 1: Pain"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.89","value":"-0.5"},{"groupId":"OG001","spread":"6.40","value":"3.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Cycle 3 Day 1: Appetite Loss"}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"description":"EORTC-QLQ-C30 is the European Organization for Research and Treatment of Cancer - Quality of Life Questionnaire - Core Questionnaire. For EORTC QLQ-C30, subscales of physical functioning, pain, and appetite loss were assessed. These had 4 response levels (not at all, a little, quite a bit, and very much). For functional scales, higher scores=better QOL (positive change from Baseline=improvement). For symptom scales, lower scores=better QOL (negative change from Baseline=improvement). Using linear transformation, raw scores were standardized, so that scores ranged from 0 to 100.","dispersionType":"Standard Error","groups":[{"description":"Participants received AG-120 500 mg, tablet, orally, QD in each 28-day treatment cycle, until occurrence of disease progression, unacceptable toxicity, confirmed pregnancy, death, subject withdrawal, lost to follow-up, or the sponsor ended the study for up to approximately 45 months.","id":"OG000","title":"AG-120"},{"description":"Participants received AG-120 matched placebo, orally, QD in each 28-day treatment cycle, until occurrence of disease progression, unacceptable toxicity, confirmed pregnancy, death, subject withdrawal, lost to follow-up or the sponsor ended the study for up to approximately 7 months. Participants who experienced disease progression and received placebo were allowed to cross over and receive AG-120.","id":"OG001","title":"Placebo"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"ITT population included all randomized participants, with treatment group designated according to the randomization. Overall Number of Participants Analyzed is the number of participants with data available for analyses at baseline and the given post-baseline timepoints. Number Analyzed at a particular timepoint is the number of participants with data available for analyses at baseline and given timepoint.","reportingStatus":"POSTED","timeFrame":"Cycle 2 Day 1 and Cycle 3 Day 1","title":"Change From Baseline in Health-Related Quality of Life (HRQOL) Based on European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire- Core 30 Subscales Scores","type":"SECONDARY","unitOfMeasure":"score on a scale"}